Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
https://www.zacks.com/stock/news/2254013/alkermes-alks-alks-2680-betters-wakefulness-in-phase-ib-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254013
Apr 11, 2024 - Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
0
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
https://www.zacks.com/stock/news/2249176/axsome-axsm-begins-solriamfetol-binge-eating-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249176
Apr 02, 2024 - Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
0
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
https://www.zacks.com/stock/news/2247989/why-is-jazz-jazz-up-1-3-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2247989
Mar 29, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Monfort Cos. wants to demolish El Chapultepec building. Historic preservationists are fighting it.
https://www.denverpost.com/2024/03/12/el-chapultepec-historic-preservation-petition-demolition-monfort-companies/
Mar 12, 2024 - Historic Denver this week filed an application for historic protection of the property at 1962 Market St.
0
Avadel surges after royalty rate awarded to Jazz in patent dispute lower than requested (update)
https://seekingalpha.com/news/4075588-avadel-drops-after-jury-rules-in-favor-of-jazz-pharmaceuticals-in-patent-dispute?source=feed_sector_healthcare
Mar 04, 2024 - Avadels stock seesawed after a jury ruled in favor of Jazz Pharmaceuticals in a patent dispute over a sleep disorder drug.
0
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
https://www.zacks.com/stock/news/2233984/jazz-jazz-q3-earnings-lag-revenues-in-line-with-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2233984
Feb 29, 2024 - Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
0
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings
https://www.zacks.com/stock/news/2233496/here-s-what-key-metrics-tell-us-about-jazz-jazz-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2233496
Feb 28, 2024 - The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
https://www.zacks.com/stock/news/2233401/jazz-pharmaceuticals-jazz-q4-earnings-lag-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233401
Feb 28, 2024 - Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS
https://www.zacks.com/stock/news/2230836/exploring-analyst-estimates-for-jazz-jazz-q4-earnings-beyond-revenue-and-eps?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2230836
Feb 23, 2024 - Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
https://www.zacks.com/stock/news/2229451/axsome-axsm-stock-falls-despite-q4-earnings-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2229451
Feb 21, 2024 - Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
0
Pages: 12
Page 1